European Journal of Health Economics

Article	Citations
Education and medication use later in life and the role of intelligence	84
Beyond 10-year lead-times in EQ-5D-5L: leveraging alternative lead-times in willingness-to-accept questions to capture preferences for worse-than-dead states and their implication	51
Should Scotland provide genome-wide sequencing for the diagnosis of rare developmental disorders? A cost-effectiveness analysis	38
Pragmatic randomized controlled trial comparing a complex telemedicine-based intervention with usual care in patients with chronic conditions	36
Psychometric properties and general population reference values for PROMIS Global Health in Hungary	32
Comparing the measurement properties of the EQ-5D-Y-3L, EQ-5D-Y-5L and CHU9D in children and adolescents: a measurement property study	29
Correction to: Geographic distribution of physicians in Portugal	25
Patient-level cost analysis of subfertility pathways in the Dutch healthcare system	24
The hidden cost of sophistication: economic complexity and obesity	22
Cost-effectiveness of transcatheter aortic valve implantation in patients at low surgical risk in France: a model-based analysis of the Evolut LR trial	22
Cost-effectiveness of adding oseltamivir to primary care for influenza-like-illness: economic evaluation alongside the randomised controlled ALIC4E trial in 15 European countries	22
Workload and short sickness absences in a cohort of Finnish hospital employees	21
Expensive today but cheaper tomorrow: lifetime costs of an active middle ear implant compared to alternative treatment options	21
Comparative cost-effectiveness of nivolumab first-line and second-line therapy for advanced esophageal cancer in Japan	21
Replay to: Comparison of EQ-5D-5 L and EORTC QLU-C10D utilities in gastric cancer patients	19
Nothing about us, without us? A reflection on and call for involving children in the process of valuing child health	19
Prescription opioids and economic hardship in France	19
Cost awareness among intensivists in their daily clinical practice: a prospective multicentre study	19
Primary care services and emergency department visits in blended fee-for-service and blended capitation models: evidence from Ontario, Canada	18
Setting incentives right with long-term risk adjustment	18
Economic assessment of abemaciclib for the adjuvant treatment of luminal HER2- breast cancer from the perspective of the Spanish health system	17
From test to rest: evaluating socioeconomic differences along the COVID-19 care pathway in the Netherlands	17
Informing decisions in light of parameter uncertainty – an economic evaluation of the adjuvanted recombinant herpes zoster vaccine in Sweden	16
On spillovers in economic evaluations: definition, mapping review and research agenda	15
The causal effect of catastrophic health expenditure on poverty in Poland	15

Multinational stakeholder engagement to inform future development and refinement of the EuroQol toddler and infant populations (EQ-TIPS)	15
Comparing EQ-5D-5L and SF-6Dv2 utilities with QLU-C10D utilities in hematologic cancer patients	15
Impact of postoperative in-hospital continuous vital sign monitoring on healthcare costs, resource utilization and labor market outcomes	15
Health-related quality of life in patients with alcohol use disorder: comparing instruments and mapping from clinical measures to preference-based measures	15
Mobile money and households’ ability to respond to health shocks in Africa: Evidence from Madagascar	14
Trends in NICE technology appraisals of non-small cell lung cancer drugs over the last decade	14
Life-cycle health effects of compulsory schooling	13
Cost-effectiveness of encorafenib with binimetinib in unresectable or metastatic BRAF-mutant melanoma	13
Breaking the rules: decision-making under absolute resource constraints	13
The EORTC QLU-C10D is a valid cancer-specific preference-based measure for cost-utility and health technology assessment in the Netherlands	13
Correction: AOTMiT reimbursement recommendations compared to other HTA agencies	12
Availability of pharmacological treatments for multiple myeloma in Spain	12
The trade-off between health system resiliency and efficiency: evidence from COVID-19 in European regions	12
Healthcare resource utilization and costs of letermovir for cytomegalovirus-prophylaxis after allogeneic hematopoietic cell transplantation in a real-world, multi-centre study in Germany	12
Hospital resource utilisation from HPV-related diseases in England: a real-world cost analysis	12
How perceptions of bone marrow donation costs affect donation behavior: survey evidence from a large donor registry	12
Do EQ-5D-Y-3L value sets have common properties, and how do they compare to EQ-5D-5L value sets?	11
Analyzing nurses’ decisions to leave their profession—a duration analysis	11
Sex differences in care complexity and cost of cardiac-related procedures as a basis for improving hospital payments systems	11
Antivirals to prepare for surges in influenza cases: an economic evaluation of baloxavir marboxil for the Netherlands	11
Is next generation sequencing for the diagnosis of rare diseases worth its cost? A user-based approach to valuation	11
Costs attributable to hypercholesterolemia in a single period and over the life cycle	11
Benefits beyond health in the willingness to pay for a quality-adjusted life-year	11
The cost-effectiveness of value-based insurance design initiatives in managing cardiometabolic diseases: a systematic review	11
Economic value of diastasis repair with the use of mesh compared to no intervention in Italy	11
Healthcare costs of foodborne diseases in the United States: an analysis using electronic health records	10
Time value of informal care of people with alzheimer’s disease in Spain: a population-based analysis	10
Demographic and health impacts of women’s bodily autonomy: switching prescription requirements for emergency contraceptives	10
Does chronic disease coverage for outpatient care affect healthcare utilization and expenditures in China? Evidence from an administrative claim dataset	10
A principled approach to non-discrimination in cost-effectiveness	10
Estimating loss in capability wellbeing in the first year of the COVID-19 pandemic: a cross-sectional study of the general adult population in the UK, Australia and the Netherlands	10
Adverse selection and consumer inertia: empirical evidence from the Dutch health insurance market	10
Changes in spending, quality indicators, and provider experiences following the introduction of a population-based payment model in dutch primary care: a mixed methods evaluation	10
The impacts of working from home on individual health and well-being	10
The social value of gambling: surplus estimates by gambling types for France	10
Is ultra-hypo-fractionated radiotherapy more cost-effective relative to conventional fractionation in treatment of prostate cancer? A cost–utility analysis alongside a randomized HYPO-RT-PC trial	10
Does prescribing apixaban or rivaroxaban versus warfarin for patients diagnosed with atrial fibrillation save health system costs? A multivalued treatment effects analysis	10
Do mobile hospital teams in residential aged care facilities increase health care efficiency: an evaluation of French residential care policy	10
Valuation of the EQ-5D-3L in Jordan	9
Does medial tourism promote growth in healthcare sector?	9
Measuring and decomposing income inequalities in child and adolescent mental health in the UK	9
Cancer specific health utilities - QLU-C10D country value sets for Belgium, Hungary, Portugal and the Republic of Korea – an international valuation study	9
Alcohol prices, the April effect, and the environment, in violence-related injury in England and Wales	9
Pharmacy cost groups for the German morbidity-based risk compensation scheme	9
Estimating QALYs in adults with cerebral palsy: mapping the San Martin scale to the EQ-5D-5L for economic evaluation	9
Modeling the potential efficiency of a blood biomarker-based tool to guide pre-hospital thrombolytic therapy in stroke patients	9
Scales and size-quality outcomes in adult learning disability residential care: evidence from the UK	9
Modeling European health systems: an ideal chain of services	9
How tax structures for retail cannabis shape cannabis use among youth and young adults: evidence from a volumetric choice experiment	9
Cost-effectiveness analysis (CEA) of ovarian cancer preventive strategies for women with BRCA1/2 pathogenic variants: the role of surveillance	8

Survival analysis of cancer patients in Portugal following the reference centre model implementation	8
How are patient inputs considered in HTA? A thematic document analysis of NICE ultra-rare disease appraisals	8
Change in healthcare resource use and associated costs of patients with metastatic lung cancer between 2013 and 2021: an observational study from the French national health data system	8
The ACA Medicaid expansions and abortion rates among young adults	8
Economic evaluation on dental caries preventive interventions for Australian children using a priority-setting approach	8
Significant healthcare burden and life cost of spinal muscular atrophy: real-world data	8
Tenders for generics and biosimilars: a challenging purchasing policy	8
Obtaining preference scores for an abbreviated self-completion version of the Teen-Addiction Severity Index (ASC T-ASI) to value therapy outcomes of systemic family interventions: a discrete choice ex	8
The link between physician motivation and care	7
Costs of productivity loss up to two years after ischaemic stroke	7
Economics of hypothalamic obesity in patients with craniopharyngioma and other rare sellar/suprasellar tumors	7
Personnel shortages and the provision of long-term care: an empirical analysis of German nursing homes	7
Challenges for health systems seeking to embrace virtual health care for population health	7
Assessment of health state utilities associated with adult and pediatric acid sphingomyelinase deficiency (ASMD)	7
Cost-effectiveness of two online interventions supporting self-care for eczema for parents/carers and young people	7
Self-interest, positional concerns and distributional considerations in healthcare preferences	7
Does diagnostic testing always decrease antibiotics prescriptions?	7
Public preferences for saving lives versus life-years: evidence from a person-trade-off experiment in 12 countries during the COVID-19 pandemic	7
Cost-utility of cochlear implantation in single-sided deafness and asymmetric hearing loss: results of a randomized controlled trial	7
The pass-through of excise taxes to market prices of heated tobacco products (HTPs) and cigarettes: a cross-country analysis	7
Measuring outcomes for loneliness research: examining the appropriateness of the EQ-5D-5 L and EQ-HWB	7
Healthcare costs of diabetic foot disease in Italy: estimates for event and state costs	7
Referring physicians' intention to use hospital report cards for hospital referral purposes in the presence or absence of patient-reported outcomes: a randomized trial	7
Recovery of suspended reimbursements of high-cost drugs subjected to monitoring registries and negotiated agreements (MEAs): a tool for governance and clinical appropriateness in the Italian reality	7
Health state utilities associated with X-linked retinitis pigmentosa (XLRP)	6
A critical review of the use of R2 in risk equalization research	6
Does health technology assessment compromise access to pharmaceuticals?	6
Generating EQ-5D-3L health utility scores from the Edinburgh Postnatal Depression Scale: a perinatal mapping study	6
Modeling European health systems: a theoretical exercise	6
One week versus three to five weeks of plaster cast immobilization for nonreduced distal radius fractures, a cost effectiveness analysis embedded in a stepped wedge cluster randomized controlled trial	6
Ex ante evaluation of risk adjustment models for prospective provider payment: a conceptual framework and empirical application	6
Estimating cost savings from reducing antibiotic overprescription in european general practices	6
Long-term costs associated with healthcare use of people with cancer in Scotland	6
Paid and unpaid productivity losses across 28 European countries due to excess deaths and COVID-19 deaths from 2020 to 2023	6
Trends and drivers of pharmaceutical expenditures from systemic anti-cancer therapy	6
Unravelling heterogeneity in efficiency measurements: a case study of public hospitals in Spain	6
The health and long-term care costs in the last year of life in The Netherlands	6
A cross-country comparison of the psychometric performance of SF-6Dv2 and EQ-5D-5L	6
A hearing bolt-on item increased the measurement properties of the EQ-5D-5L in a community-based hearing loss screening program	6
Time preferences and COVID-19 vaccination uptake	6
The effect of displaying laboratory test prices on physicians’ ordering behaviour: a systematic review of European studies	6
Impact of the introduction of the AMNOG law on launch delays of new drugs in Germany: a comment	6
Inpatient care utilisation and expenditure associated with objective physical activity: econometric analysis of the UK Biobank	6
Assessing Taiwan’s pay-for-performance program for diabetes care: a cost–benefit net value approach	6
Disclosing the ‘Big C’: what does cancer survivorship signal to employers?	6
Obesity and metabolic state are associated with increased healthcare resource and medication use and costs: a Finnish population-based study	6
Comparing EQ-5D-5L, PROPr, SF-6D and TTO utilities in patients with chronic skin diseases	6
A systematic review of economic models comparing in-centre haemodialysis interventions: challenges for demonstrating cost-effectiveness in the context of high background dialysis costs	5
EQ-5D-5L Portuguese population norms	5
Non-communicable diseases, COVID-19 and labour market outcomes	5
Economic burden of eosinophilic esophagitis in the first year after diagnosis in Spain: A direct medical cost analysis	5
Assessing the economic burden of complicated urinary tract infection: A systematic literature review	5
The performance of the EQ-HWB-S as a measure of quality-of-life of caregivers in families that have experienced adverse events	5
Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy	5
Total costs of different lines of treatment in diffuse large B-cell lymphoma in Denmark – a real-world data analysis	5
Willingness to pay for a quality adjusted life year across different time horizons: direct elicitation in Quebec	5
Does opt-out legislation crowd out living organ donations? A cross-country study	5
Risk, time preferences, trustworthiness and COVID-19 preventive behavior: evidence from France	5
Health sector corruption and access to healthcare in Africa	5
Validity and responsiveness of EQ-5D-Y in children with haematological malignancies and their caregivers	5
Cost-effectiveness of the MitraClip device in German heart failure patients with secondary mitral regurgitation	5
Translating the EORTC CAT core and the QLQ-C30 to the EQ-5D-5L in patients with metastatic breast cancer: A comparison of direct and indirect mapping algorithms	5
Long-term effectiveness and cost-effectiveness of testing for alemtuzumab antidrug antibodies to guide treatment in multiple sclerosis: a modelling study	5
Cost-effectiveness analysis of the covered endovascular reconstruction of the aortic bifurcation versus kissing stents and open surgical repair for the treatment of aorto-iliac occlusive disease	5
Breaking the habit: a systematic review of the cost-effectiveness of non-pharmacological and combined interventions for smoking cessation in Europe	5
Were we happy and we didn’t know it? A subjective dynamic and financial assessment pre-, during and post-COVID-19	5
Mapping of the EORTC QLQ-LC43 to EQ-5D-5 L index in patients with lung cancer: comparison of traditional regression models with machine learning technique	5
Cost-effectiveness and cost-utility analysis of a nurse-led, transitional care model to improve care coordination for patients with cardiovascular diseases: results from the “Cardiolotse” study	5
The societal cost of ‘unwanted’ loneliness in Spain	5
Correction: Lifetime direct healthcare costs of treating colorectal cancer: a systematic review	5
Does the inclusion of societal costs change the economic evaluations recommendations? A systematic review for multiple sclerosis disease	5
Productivity costs associated with premature deaths due to acute myocardial infarction in Spain: analysis from 2013 to 2022	5
The inpatient economic burden of antibiotic resistance in Switzerland: a regression-based analysis	4
A cost-of-illness study of Behçet syndrome in Italy	4
A novel mathematical model for prioritization of individuals to receive vaccine considering governmental health protocols	4
Cost-effectiveness analysis of influenza vaccination with high-dose vaccine versus standard-dose quadrivalent vaccine in older adults in Spain	4
The value of social robots supporting informal care: a discrete choice experiment among informal caregivers	4
Health technology assessment criteria as drivers of coverage with managed entry agreements: a case study of cancer medicines in four countries	4
Out-of-pocket costs sustained in the last 12 months by cancer patients: an Italian survey-based study on individual expenses between 2017 and 2018	4
The effect of age-specific stay-at-home recommendation on healthcare utilization: Evidence from Finland’s COVID-19 policy	4

Informal care at old age at home and in nursing homes: determinants and economic value	4
New evidence on supplier-induced demand in China’s public tertiary hospitals: is the cost of hospitalization higher in the off-season?	4
A systematic review of the cost-effectiveness of interventions to increase cervical cancer screening among underserved women in Europe	4
Public versus private healthcare systems in the OECD area– a broad evaluation of performance	4
Shaping a suitable EU HTA dossier template: why the German template is not fit for purpose	4
Loss aversion in EQ-5D-Y-3L: does it explain differences in willingness to trade-off life years in adults and children?	4
The handling of missing data in trial-based economic evaluations: should data be multiply imputed prior to longitudinal linear mixed-model analyses?	4
The Impact of Health Technology Assessment on Pharmaceutical Prices: Evidence from Germany	4
The effect of telephone health coaching and remote exercise monitoring for peripheral artery disease (TeGeCoach) on health care cost and utilization: results of a randomized controlled trial	4
Making the rules make sense: valuation of constrained resources	4
Valuation of EQ-5D-5L health states from cancer patients’ perspective: a feasibility study	4
Critical issues with methods and results interpretation at validating the EQ-5D-5L and QLU-C10D utilities in gastric cancer patients	4
Does a free maternity policy in Kenya work? Impact and cost–benefit consideration based on demographic health survey data	4
Variation in patient-reported outcomes after total hip replacement across ten high-volume hospitals in Germany: results from a multicenter, prospective, longitudinal Cohort Study	4
Migration-related determinants of health-care service utilization among persons with a direct migration background in Germany: an exploratory study based on the German Socio-Economic Panel (SOEP)	4
Broadening sources of finance for health promotion and disease prevention: Smart capacitating investment	4
Assessing the relation between financial performance and long-term bank loan interest rates for healthcare providers in the Netherlands: a panel data analysis	4
Comparison of four approaches in eliciting health state utilities with SF-6Dv2	4
Is there a link between health care utilisation and subjective well-being? An exploratory study among older Danes	3
The EQ-5D-3L valuation study for Bermuda: using an on-line EQ-VT protocol	3
Nexus among health expenditures, ICTs and sustainable economic growth: Insights from South Asian Nationals health and economic issues	3
Cancer-specific utility: clinical validation of the EORTC QLU-C10D in patients with glioblastoma	3
Costs associated with insufficient physical activity in Germany: cross-sectional results from the baseline examination of the German national cohort (NAKO)	3
A state-level analysis of macro-level factors associated with hospital readmissions	3
Comparison of EQ-5D-5L and EORTC QLU-C10D utilities in gastric cancer patients	3
Cost-effectiveness analysis alongside the inter-B-NHL ritux 2010 trial: rituximab in children and adolescents with B cell non-Hodgkin’s lymphoma	3
Exploring non-iterative time trade-off methods for valuation of EQ-5D-5L health states	3
TF-TAVI and SAVR post-procedural complications in Germany 2021/2022 – impact on healthcare resource consumption	3
What remains after the money ends? Evidence on whether admission reductions continued following the largest health and social care integration programme in England	3
The add-on list cannot do it all: a comparative economic evaluation of equity impacts in the German and French inpatient care sectors	3
Repurposing biosimilars, rethinking costs: a framework for sustainable drug pricing for repurposed bevacizumab for intravitreal injections	3
Cost-effectiveness of Mavacamten for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy using a French healthcare perspective	3
Future medical and non-medical costs and their impact on the cost-effectiveness of life-prolonging interventions: a comparison of five European countries	3
The impact of parastomal hernia on quality of life using data from the CIPHER prospective cohort study	3
Promoting healthy behaviour with financial incentives: three challenges and solutions for large scale implementation	3
Routine measurement in low back pain; towards a pragmatic patient-reported productivity cost outcome measurement using the institute for medical technology assessment productivity cost questionnaire	3
Estimating surgery, radiotherapy and systemic anti-cancer therapy treatment costs for cancer patients by stage at diagnosis	3
Economic and human burden attributable to antimicrobial resistance in Spain: a holistic macro-estimation of costs	3
Early start of anti-dementia medication is associated with lower health and social care costs in Alzheimer´s patients: a Finnish nationwide register study	3
Cost-effectiveness analysis of procalcitonin and lung ultrasonography guided antibiotic prescriptions in primary care	3
Test-retest reliability of the Online Elicitation of Personal Utility Functions (OPUF) approach for valuing the EQ-HWB-S	3
Short- and intermediate-term impact of DTC telemedicine consultations on subsequent healthcare consumption	3
Comparing the measurement properties of the EQ-5D-5 L, SF-6Dv2, QLU-C10D and FACT-8D among survivors of classical Hodgkin’s lymphoma	3
United Kingdom value set for the functional assessment of cancer therapy eight dimension (FACT-8D) preference-based quality of life instrument	3
Population normative data for OxCAP-MH capability scores	3
Impact of Long COVID on productivity and informal caregiving	3
The economic burden of asthma in Italy: evaluating the potential impact of different treatments in adult patients with severe eosinophilic asthma	3
Comparison of the EQ-5D-Y and the CHU-9D instruments in a general child population based on self-reports and proxy-reports	3
Are there differences in health state preferences between urban and rural respondents? a comparison using time trade-off and discrete choice experiment	3
Willingness to pay for measures to increase use of active school transport	3
“COVID-19 and income inequality in OECD countries:” A methodological comment	3
The EORTC QLU-C10D: the Hong Kong valuation study	3
How do family doctors respond to reduced waiting times for cancer diagnosis in secondary care?	2
Using machine learning to estimate health spillover effects	2
Changes in disposable income of Polish households and growing trends in alcohol mortality	2
Healthcare information management and operational cost performance: empirical evidence	2
Exploring the social value and design preferences for a home-based dementia community program in Australia	2
Do institutions matter for citizens’ health status? Empirical evidence from Italy	2
How a nation’s well-being influences its health profile: an analysis of critical indicators	2
Population norms for the EQ-5D-5L for Hungary: comparison of online surveys and computer assisted personal interviews	2
Bridging success in the labour market: does continuity of general practitioners’ care matter for individuals with common mental disorders?	2
Apixaban versus other anticoagulants in patients with nonvalvular fibrillation: a comparison of all-cause and event-related costs in real-life setting in France	2
Far more than a shot in the arm: Vaccines and consumer spending	2
The economic burden of idiopathic pulmonary fibrosis in Australia: a cost of illness study	2
Incentivizing adherence to pre-exposure prophylaxis for HIV prevention: a randomized pilot trial among male sex workers in Mexico	2
Tough versus soft regulations to promote generic medications in Italy	2
To what extent does the use of crosswalks instead of EQ-5D value sets impact reimbursement decisions?: a simulation study	2
Dividend policy issues in the European pharmaceutical industry: new empirical evidence	2
Burden of myelodysplastic syndromes: a systematic literature review of economic burden	2
Nonprofit behavior altered by monetary donations: evidence from the U.S. hospice industry	2
Cost-effectiveness of TAVI in the United Kingdom: a long-term analysis based on 4-year data from the Evolut Low Risk Trial	2
Cost analysis of transthyretin amyloid cardiomyopathy in heart failure patients with preserved ejection fraction in Spain	2
Pembrolizumab vs. chemotherapy in the first-line setting of PD-L1 ≥ 50% metastatic non-small cell lung cancer: a real-world cost-effectiveness analysis	2
Age, morbidity, and time to death: End-of-life expenditures on health care for the young-old population	2
Estimating the willingness-to-pay to avoid the consequences of foodborne illnesses: a discrete choice experiment	2
Is EQ-5D-5L better than EQ-5D-3L? A comparison of descriptive systems and utility scores in patients with kidney chronic disease	2
Measuring EQ-5D-5L utility values in parents who have experienced perinatal death	2
Monetary value of health—a practical decision-making framework combining equity considerations and WTP	2
Time and lexicographic preferences in the valuation of EQ-5D-Y with time trade-off methodology	2
The added value of the cognition, dining, gastrointestinal problems, sleep and tiredness bolt-on dimensions to the EQ-5D-5L in patients with coeliac disease	2
Points to consider for incorporating climate impacts into health economic evaluation	2
Cash-for-care and its impact on older adults’ informal and formal long-term care use: evidence from continental European countries	2
Willingness to pay for health gains from an international integrated early warning system for infectious disease outbreaks	2
Country-level effects of diagnosis-related groups: evidence from Germany’s comprehensive reform of hospital payments	2
Does uptake of specialty care affect HRQoL development in COPD patients beneficially? A difference-in-difference analysis linking claims and survey data	2
Length of hospital stays and financial incentives: evidence from Dutch rehabilitation centers	2
A Spanish value set for the SF-6D based on the SF-12 v1	2
Out-of-pocket expenses of patients with inflammatory bowel disease: a comparison of patient-reported outcomes across 12 European countries	2
Lifetime direct healthcare costs of treating colorectal cancer: a systematic review	2
Health shocks and health behavior: a long-term perspective	2
Completing the time trade-off with respondents who are older, in poorer health or with an immigrant background in an EQ-5D-5L valuation study	2
Bayesian cost-effectiveness analysis of Whole genome sequencing versus Whole exome sequencing in a pediatric population with suspected genetic disorders	2
The causal effect of early retirement on medication use across sex and occupation: evidence from Danish administrative data	2
A model-based cost-effectiveness analysis of prescribing by dietitians and therapeutic radiographers in England	2
The formal care costs of dementia: a longitudinal study using Swedish register data	2